Status:
COMPLETED
Long Term Study With B2036-PEG
Lead Sponsor:
Pfizer
Conditions:
Acromegaly
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Eligibility Criteria
Inclusion
- Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009).
Exclusion
- Switching to other therapeutic methods for acromegaly
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00143416
Start Date
April 1 2004
End Date
July 1 2007
Last Update
July 29 2008
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kobe, Hyogo PREF, Japan, 650-0017
2
Pfizer Investigational Site
Kozukue-cho, Kouhoku-ku, Yokohama-shi, Kanagawa, Japan, 222-0036
3
Pfizer Investigational Site
Kyoto, Kyoto, Japan, 612-8555
4
Pfizer Investigational Site
Hamamatsu, Shizuoka, Japan, 431-3124